What HollandPTC does

HollandPTC (Holland Protonen Therapie Centrum) is an independent outpatient proton therapy center located in Delft, Netherlands, founded in 2018 by a consortium of three Dutch institutions: Erasmus MC (Rotterdam), LUMC (Leiden), and TU Delft. The center operates under a WBMV (Wet Bijzondere Medische Verrichtingen) license granted by the Dutch Ministry of VWS in December 2013, with a statutory annual treatment capacity of 600 patients. Its core clinical offering is proton therapy — using accelerated protons rather than photons to exploit the Bragg peak effect, depositing maximum radiation dose in the tumor while sparing surrounding healthy tissue. The facility houses three treatment rooms (De Luit, De Citer, and De Parel, the last specialized for ocular melanoma), and is the only center in the Netherlands authorized to treat ocular tumors with protons; pediatric cases are referred to UMCG in Groningen.

The technology stack includes pencil-beam scanning, image-guided adaptive proton therapy integrating CT/MRI/PET-CT, and a research pipeline covering FLASH proton therapy (≥40 Gy/s) and real-time in-vivo dosimetry using sub-100 picosecond PET detectors. Beyond clinical care, HollandPTC runs a substantial research program across clinical studies, high-precision technology, health economics, FLASH, and combination therapies, with technology and research partnerships with Varian Medical Systems, Siemens Healthineers, Philips, RaySearch Laboratories, and academic networks including EPTN, DUPROTON, and Medical Delta.

Commercially, HollandPTC generates revenue from proton therapy treatment services reimbursed by Dutch mandatory health insurance. Standard indications (ocular melanoma, skull-base chordomas/chondrosarcomas, seminoma, pediatric cases via Groningen) are automatically reimbursed; model-based indications (breast, head/neck, lung, lymphoma, esophageal) require a national plan comparison demonstrating superior risk profiles. International and self-pay patients are billed at passerentarieven set by the Nederlandse Zorgautoriteit. Go-to-market is referral-based: Dutch hospital radiotherapist-oncologists assess eligibility and refer patients through the standardized TWIIN portal, with additional commercial access offered to research users via the Beamtime Call mechanism.

Name

HollandPTC

Legal name

HollandPTC

Website

https://hollandptc.nl

Company type

Private

Founded year

2018

Operating status

Operating

Headcount range

11–50 employees

Short description

HollandPTC is a Dutch outpatient proton therapy center in Delft, founded by Erasmus MC, LUMC, and TU Delft, delivering precision proton radiation for cancer patients under a WBMV-licensed 600-patient annual capacity while conducting clinical and physics research.

Ownership category

akta.pro rank

Product category

Proton Therapy / Radiation Oncology

NAICS

Diagnostic Imaging Centers (621512), Scientific Research and Development Services (5417)

SIC

Services-Offices & Clinics Of Doctors Of Medicine (8011), Services-Health Services (8000)

akta.pro primary industry

Radiation Oncology (HLAKAFAC)

akta.pro secondary industries

Nuclear Medicine Clinical Services & Therapy Centers (HLAIAGAI), Radiation Therapy Planning & Simulation Imaging (CT Sim/MR Sim) (HLAHABAH)

Keywords

• Proton therapy
• Radiation oncology
• Cancer treatment center
• Ocular melanoma treatment
• Particle therapy

Headquarters

HQ city

Delft

HQ country

Netherlands

HQ region

Europe

Offices1 record

Markets served

GTM type

B2C

Offering type

Services

Cost components

Infrastructure, Personnel, Technology or R&D, Operations, Marketing or Sales

Revenue model

1. Proton therapy treatment services: HollandPTC provides proton therapy treatment services reimbursed by Dutch health insurers. For standard indications, proton therapy is automatically covered by insurance. For model-based indications, a treatment plan comparison determines eligibility and coverage. International patients without Dutch insurance pay passer tariffs. Treatment costs are covered by mandatory Dutch health insurance, with patients responsible for their deductible (eigen risico).

Pricing tiers

Go-to-market motion1 record

Distribution channels1 record

Marketing channels6 records

Core offering

HollandPTC is an independent outpatient proton therapy center that delivers precise radiation treatment to cancer patients using accelerated proton beams, exploiting the Bragg peak to concentrate dose in tumors while sparing surrounding healthy tissue. In addition to clinical care, the center conducts scientific research in biology, physics and technology, and clinical studies, and runs education programs for radiation oncologists, medical physicists, and radiotherapy technologists.

Product overview

HollandPTC (Holland Protonen Therapie Centrum) is a specialized proton therapy center founded by Erasmus MC, LUMC, and TU Delft. The organization operates three core functions: patient care (Protonentherapie), scientific research (Wetenschappelijk Onderzoek), and education (Onderwijs). Patient care includes precise proton radiation treatment for various cancers using three treatment rooms named Luit, Citer, and Parel. The research program covers five themes: Clinical Studies, High-Precision Proton Therapy, Health Economics, Flash Proton Therapy, and Combined Treatment Research. HollandPTC also operates a specialized Eye Treatment Line for ocular melanoma, the only such center in the Netherlands. The organization develops custom in-house software and hardware for treatment planning and delivery, though these are internal tools rather than commercial products.

Differentiator

Problem solved

Functional benefit

Products and services

• Proton Therapy (Protonentherapie) Precise radiation therapy using accelerated protons instead of photons to treat cancer, enabling targeted tumor irradiation with reduced damage to surrounding healthy tissue and lower side effects. Provided to cancer patients referred by Dutch radiotherapist-oncologists.
• Patient Care (Patiëntenzorg) Comprehensive patient care service including treatment planning, radiation delivery, and follow-up monitoring for proton therapy patients treated at HollandPTC.
• Scientific Research (Wetenschappelijk Onderzoek) Cross-disciplinary research program focused on enhancing the added value of proton therapy through biology, physics & technology, and clinical studies. Includes research projects, researcher teams, and publication output.
• Education and Knowledge Sharing (Onderwijs en Kennisdeling) Educational programs and knowledge sharing for radiation oncologists, clinical physicists, radiotherapy technologists, and technical personnel. Includes Boerhaave Nascholing e-learning and access to clinical and pre-clinical facilities.
• HollandPTC Eye Treatment Line (Ooglijn) for Ocular Melanoma Specialized proton therapy treatment line for ocular melanoma using advanced techniques including clipless MR-eye guided planning, delivered in the dedicated De Parel treatment room. Provided to ocular melanoma patients in the Netherlands.
• Plan Comparison (Planvergelijking) Clinical service comparing photon radiation treatment plans with proton therapy plans for individual patients with model-based indications to determine whether proton therapy offers better outcomes with fewer side effects, including ΔNTCP-based eligibility assessment.
• Clinical Studies at HollandPTC Clinical research evaluating accepted and new clinical indications and testing new treatment strategies including hypofractionation, adaptive proton therapy, and combination therapy.
• High-Precision Proton Therapy Research Research program focused on enhancing proton therapy through development and implementation of new technology and methodologies including advanced pre-treatment imaging, online adaptation, motion mitigation, AI use, and automated and probabilistic treatment planning.
• Health Economics Research Research program assessing the health-economic benefits of proton therapy to determine its value, cost-effectiveness, and identify opportunities to maximize effectiveness and efficiency, led through collaboration with Erasmus University Rotterdam.
• FLASH Proton Therapy Research Research program dedicated to understanding, developing, and clinically testing ultra-high dose rate proton therapy (≥40 Gy/s) with specific focus on the FLASH effect.
• Combined Treatment Research Research program investigating proton therapy interaction with other treatments such as immunotherapy, hyperthermia, and targeted drugs to maximize treatment effectiveness in clinical practice.

Quantifiable outcome

• Health insurers reimburse treatment for standard indications automatically
• +3 more outcomes

Named customers6 records

Segments3 records

Ideal customer profiles5 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature4 records

Partnerships

Twelve partnerships are on record, tiered core, major and minor.

• Erasmus MCcoreStrategic or Co-development Partner · 1 January 2018Founding partner and major clinical collaborator. Erasmus MC radiotherapist-oncologists supervise treatments and conduct joint research. Prof. dr. Mischa Hoogeman serves as Principal Investigator. The partnership provides clinical expertise in radiotherapy and oncology, with joint research programs in proton therapy optimization and clinical outcomes.
• LUMC (Leiden University Medical Center)coreStrategic or Co-development Partner · 1 January 2018Founding partner and clinical collaborator. LUMC radiotherapist-oncologists including Prof. dr. Coen Rasch supervise treatments. LUMC handles most ocular melanoma cases in the Netherlands (over 90%) and refers appropriate patients for proton therapy. Joint research in proton therapy for chordomas, vestibular schwannomas, and ocular melanoma.
• TU DelftcoreStrategic or Co-development Partner · 1 January 2018Founding partner providing technical/physics expertise. TU Delft hosts HollandPTC on its campus. Joint research in proton therapy physics, imaging technology, treatment planning optimization, and AI applications. Prof. dr. Roland Kanaar and Prof. dr. Mischa Hoogeman (also Erasmus MC) lead research programs.
• Varian Medical SystemsmajorTechnology or IntegrationEquipment and technology partner providing proton therapy systems and treatment planning software. Multiple joint research projects funded including Proton-DDR (2019), vestibular schwannoma research (2018), real-time dosimetry (2020), and FLASH therapy development (2020). Also provides access for commercial users to HollandPTC facilities.
• Siemens HealthineersmajorTechnology or IntegrationMedical imaging technology partner providing CT and other imaging systems used in treatment planning and image guidance for proton therapy.
• PhilipsmajorTechnology or IntegrationMedical technology partner providing imaging and healthcare technology solutions supporting treatment planning and patient care operations.
• RaySearch LaboratoriesmajorTechnology or IntegrationTreatment planning software partner. Joint research project 'Probabilistic optimization and planning' funded by RaySearch Laboratories developing methods for probabilistic optimization in proton therapy treatment planning.
• European Proton Therapy Network (EPTN)majorStrategic or Co-development PartnerEuropean network of proton therapy centers collaborating on best practices, guidelines, and harmonization of proton therapy treatment planning and delivery across Europe.
• Medical DeltamajorStrategic or Co-development PartnerNetwork of life sciences, health and technology partners in the Delft-Leiden-Rotterdam region. Supports Health Technology Assessment (HTA) research and cross-institutional collaboration. Prof. dr. Coen Rasch holds Medical Delta professorship linking LUMC and TU Delft.
• InHollandminorStrategic or Co-development PartnerApplied sciences university collaborating on radiation therapy technologist (RTT) training and education. Joint project 'Towards a sustainable RTT network' funded by European Union Erasmus+ program (2023) to harmonize proton therapy planning and delivery practices across Europe.
• National DUPROTON research networkminorStrategic or Co-development PartnerDutch national research network for proton therapy collaboration among proton therapy centers in the Netherlands.
• Erasmus University Rotterdam (EUR)majorStrategic or Co-development PartnerCollaboration through Erasmus School of Health Policy and Management on health economics research. Dr. Hedwig Blommestein leads HTA value proposition research. PhD students from EUR conduct cost-effectiveness and health technology assessment studies.

Scale indicators4 records

Recent moves8 records

Expansion highlights6 records

Others

• RaySearch Laboratories: Treatment planning software vendor and HollandPTC R&D partner. Comparable as the technology ecosystem participant whose RayStation platform is used in HollandPTC's plan-comparison workflow and whose probabilistic optimization research directly shapes the center's clinical capability.

Broad incumbents

• IBA (Ion Beam Applications): Global leader in proton therapy equipment manufacturing and a broad incumbent in particle therapy. Comparable as the dominant infrastructure provider in the same clinical modality that HollandPTC operates, including competing ProteusONE/ProteusPLUS systems installed at peer centers worldwide.
• Varian Medical Systems (a Siemens Healthineers company): HollandPTC's primary equipment and treatment-planning partner (ProBeam proton system). Comparable as the major radiotherapy incumbent whose installed base of photon and proton systems at other centers competes for the same oncology referral base and whose technology roadmap directly affects HollandPTC's clinical capabilities.
• Hitachi (Hitachi High-Tech) Particle Therapy: Global proton therapy system manufacturer and operator (formerly Mitsubishi Electric). Comparable as a broad incumbent providing competing synchrotron-based proton systems installed at multiple academic medical centers, including European sites that compete for the same European patient and research demand.

Regional players

• The Christie NHS Foundation Trust (Proton Beam Therapy Centre): UK NHS proton therapy center in Manchester treating pediatric and adult cases. Comparable as a publicly funded, hospital-integrated proton therapy center operating a similar clinical-research-education model, but in a different national reimbursement system (NHS) than HollandPTC's Dutch insurer model.

Direct peers

• UMCG Protonentherapiecentrum: Proton therapy center at the University Medical Center Groningen, the other major Dutch proton facility. Directly comparable: same country, same WBMV-regulated indication framework, treats pediatric patients that HollandPTC does not, and competes for the same Dutch patient pool and referring physicians.
• Maastro Proton Therapy: Proton therapy center at Maastro Clinic in Maastricht, the third Dutch proton facility. Directly comparable as a domestic competitor operating under the same WBMV license framework, treating overlapping model-based indications, and serving the same national referral network.

Emerging players

• Provision CARES Proton Therapy Center (Nashville): US proton therapy center using Mevion compact systems. Comparable as a smaller-scale, single- or multi-room proton therapy operator with similar capital intensity and capacity dynamics, though operating under a US payer mix rather than Dutch mandatory insurance.
• Mevion Medical Systems: Compact single-room proton therapy system manufacturer targeting smaller hospitals. Comparable as an emerging alternative technology platform whose success in reducing proton therapy capex could shift the competitive landscape for small-scale centers like HollandPTC.
• Paul Scherrer Institute (PSI) – Center for Proton Therapy: Swiss research-and-treatment proton therapy center, historically the pioneer of pencil-beam scanning. Comparable as a research-driven proton therapy operation combining patient care with technology development (Gantry 2, Gantry 3) in a similar combined clinical-research model to HollandPTC.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat5 records

Key risks5 records

Key highlights6 records

Customer concentration

• Xx.com/HollandPTC
• LinkedInnl.linkedin.com/company/holland-proton-therapy-centre
• Instagraminstagram.com/hollandptc.delft?igsh=bnphaGl6ZGVnOXlq&utm_source=qr

Revenue estimate

Valuation estimate

Number of profiles

Profiles1 record

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about HollandPTC